Figure 2: YAP is required for the maintenance of basal skeletal muscle fibre size.
From: The Hippo pathway effector YAP is a critical regulator of skeletal muscle fibre size
(a) Representative western blot showing YAP and GAPDH levels in muscles treated with rAAV6:LacZ shRNA in the left TA muscle (LTA) or rAAV6:YAP shRNA in the right TA muscle (RTA) at a dose of 5 × 109 vector genomes for 2 weeks with quantification shown below. (mean±s.e.m., n=5, P=0.03, paired t-test, * indicates significance between groups). (b) Muscle mass of TA muscles treated with rAAV6:LacZ shRNA or rAAV6:YAP shRNA for 2 weeks. (mean±s.e.m., n=5, P=0.003, paired t-test, * indicates significance between groups). (c) CSA of rAAV6:LacZ shRNA- or rAAV6:YAP shRNA-treated myofibres after 2 weeks. (mean±s.e.m., n=5, P=0.03, paired t-test, * indicates significance between groups). (d) Representative images of rAAV6:LacZ shRNA- or rAAV6:YAP shRNA-treated muscles after 2 weeks. Scale bar, 50 μm. n=5. (e) Ankrd1 and (f) Ctgf mRNA expression in rAAV6:LacZ shRNA- or rAAV6:YAP shRNA-treated muscles. (mean±s.e.m., n=5, P=0.02 and 0.01 respectively; paired t-test, * indicates significance between groups). (g) Representative western blots and (h) quantification of Puromycin and GFP levels in rAAV6:LacZ shRNA or rAAV6:YAP shRNA treated muscles after 2 weeks. (mean±s.e.m., n=3, P=0.04, paired t-test, * indicates significance between groups). (i) Atrogin-1, (j) Murf1, (k) Musa1 mRNA expression in rAAV6:LacZ shRNA or rAAV6:YAP shRNA treated muscles after 2 weeks. (mean±s.e.m., n=5, P=0.32, 0.13 and 0.26 respectively, paired t-test).
